TriSalus Life Sciences, Inc. (TLSI) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -464.71%. A quarter ago, it was expected that this company would post a loss of $0.22 per share when it actually produced a loss of $0.27, delivering a surprise of -22.73%.Over the last four quarters, the com ...

Trisalus Life Sciences (NasdaqGM:TLSI) Q3 2025 Earnings Call November 13, 2025 04:30 PM ET Speaker1Afternoon and welcome to Trisalus Life Sciences' third quarter 2025 earnings conference call. Currently, all participants are on a listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session. As a reminder, this call is being recorded for replay purposes. I will now turn the call over to Jeremy Pfeffer, Managing Director with Life Sciences Advisors. Please go ahead, si ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-39813 TriSalus Life Sciences, Inc. (Exact name of registrant as specified in its charter) (S ...

TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance TriSalus Reports $11.6 million in Revenue, Up 57% Year-over-Year, Reflecting Strong Liver Embolization growth Investigator Published Data Show TriNav Enables Safe, Effective Thyroid Embolization Alternative to Surgery Reaffirmed revenue guidance of at least 50% growth due to continued commercial momentum Hosting Conference Call and Webcast today at 4:30pm ET DENVER – November 13, 2025 - TriSalus Life Sciences, Inc. ...

oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended September 30, 2025, and provides an operation update. "TriSalus continued to deliver strong commercial performance in the third quarter, underscoring the growing clinica. DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company†), an ...

TriSalus Life Sciences Inc. (NASDAQ:TLSI) is gearing up for its quarterly earnings release, with a focus on its innovative approach to oncology treatment.Here are three key insights from the upcoming financial announcement and recent company activities:- Wall Street anticipates an earnings per share (EPS) of -$0.17 and projected revenue of approximately $11.76 million.- Despite a negative price-to-earnings (P/E) ratio of -4.67, TLSI is actively engaging in investor relations events, including the Canaccord ...

PresentationGood morning, and welcome to the TriSalus Life Sciences KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the TriSalus website following the conclusion of the event.Mary SzelaCEO, President & Director Welcome, everyone, and thank you so much for joining. This is the first or our inaugural webinar in a series of webinars that help illustrate the value of our technology. And I'm very excited to report that we have two distinguishe ...

Hey everyone, Chris Versace here, portfolio manager of the Streets Pro Portfolio and welcome to this episode of the Stocks and Markets podcast. We continue to see well more than a lot of attention uh stemming from folks that are raising questions about the AI trade, but also the subsequent explosion in the demand for power to power that everexpanding data center footprint. And while the focus is on AI, the reality is that there's a lot more behind the tailwinds powering that growing pain point.To address th ...

Trisalus Life Sciences (NasdaqGM:TLSI) Update / Briefing November 12, 2025 10:00 AM ET Speaker4Good morning and welcome to the TriSalus Life Sciences KOL event. At this time, all attendees are in a listen-only mode. A question-and-answer session will follow the formal presentations. If you'd like to submit a question, you might do so by using the Q&A text box at the bottom of the webcast player. As a reminder, this call is being recorded, and a replay will be made available on the TriSalus website following ...

**Trisalus Life Sciences (TLSI) 电话会议纪要关键要点** **涉及的行业和公司** * 公司为Trisalus Life Sciences (TLSI) 一家专注于解决实体瘤治疗难题的医疗器械公司[1] * 行业属于医疗器械(MedTech) 具体领域为介入放射学(interventional radiology)和肿瘤介入治疗[1][12] **核心技术与产品** * 核心技术为压力启用药物输送(Pressure-Enabled Drug Delivery)技术 通过其TriNav微导管系统末端的微型阀门调节肿瘤内的压力和血流[3] * 该技术解决了实体瘤内压力过高导致药物无法有效输送的难题 可将进入肿瘤的疗法提升30%至500%[4] * 当前标准护理仅为普通微导管 无法调节压力或流量 导致靶向输送不足和许多并发症[5] * 产品组合正在扩大 包括基础产品、更大尺寸版本(TriNaflex)、更灵活版本以及专用于子宫肌瘤和甲状腺的新产品 旨在覆盖任何类型的血管解剖结构[10][24] **市场机会与商业进展** * 主要市场在肝脏 针对肝转移和原发性肝癌(肝细胞癌) 但应用已扩展至其他领域[8] * 市场机会从约4亿美元大幅扩展至近25亿美元[8] * 2025年上半年业绩相比2024年同期增长约50% 第二季度相比第一季度环比增长22%[9] * 增长驱动因素包括新产品的推出、报销代码的明确以及市场意识的提高[10] * 在美国1100家医院中 约400家占据了90%的此类手术量 其中前100家是最高容量的目标[17] * 公司已在这前100家目标医院中拥有57家"繁荣账户" 目标是进入全部400家并使其繁荣[21] **报销与经济效益** * 公司拥有独特的栓塞手术代码 报销针对"压力启用药物输送"程序 可在除大脑和心脏外的全身任何部位使用[12] * 报销对医院非常有利且为现金正收益 每次使用其技术可为CMS(美国医疗保险和医疗补助服务中心)每位患者节省超过8000美元[12] * 甲状腺等新应用的报销也覆盖在当前程序代码下 对医院和支付方都具吸引力[31] **销售策略与市场采用** * 销售策略从获取医院批准转向提高现有账户的使用率 并围绕核心用户建立更多医生使用 目标使每个机构有3至4名用户[13] * 销售团队经过优化 现已形成高性能的组织结构 专注于销售新的治疗方法和改变医生手术方式[15][16] * 采用的主要障碍是医生教育和意识不足 因为他们不熟悉瘤内压力和肿瘤微环境的概念[22][25] * 公司正通过大规模的注册表研究生成临床证据 旨在提交给各类治疗指南(如肝脏、内分泌、ACOG指南)[26] **新应用与临床进展** * **甲状腺栓塞**：医生创新了通过甲状腺下动脉的新方法 避免了颈动脉 降低了中风风险 手术约30至40分钟 成本远低于手术且不损伤甲状腺[28][29] * 目前有10个站点正在进行甲状腺栓塞注册研究 培训将采用类似Y90的预监模式 要求完成三例手术[30] * **子宫纤维瘤**：将推出专用于此的新产品[10] * **Nelitolimod(免疫疗法)**：Phase I研究投入将于本季度结束 数据将公开并寻求合作伙伴 用于葡萄膜黑色素瘤和胰腺癌等适应症[32] * 理想的合作伙伴应对肝脏或胰腺适应症有战略兴趣 并具备快速推进该疗法的能力和疾病知识[33] **财务状况与前景** * 2025年第二季度GAAP运营支出(OpEx)约为6000万美元 现金运营支出接近5000万美元[34] * 通过提高效率和结束nelitolimod项目支出 有望再节省300万至500万美元[34] * 公司专注于近期实现现金流收支平衡 注册表研究由于已获得报销 本质上是现金流正向的 并能提高市场对产品的认知[35] * 未来的投资将主要用于扩大销售和市场营销规模以及进行注册表研究[34] **2026年关键里程碑** * 关键催化剂包括纤维瘤、膝状动脉(genicular artery)、子宫纤维瘤的数据发布 以及下一代Advance产品的推出[36]